Silence Therapeutics PLC

XRP2

Company Profile

  • Business description

    Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

  • Contact

    72 Hammersmith Road
    LondonW14 8TH
    GBR

    T: +44 2034576900

    E: [email protected]

    https://www.silence-therapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    116

Stocks News & Analysis

stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.
stocks

ASX listed tariff play

Trump’s focus on US steel production may benefit this firm.
stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.80116.001.30%
CAC 407,822.670.670.01%
DAX 4024,289.5181.42-0.33%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,992.1219.480.22%
HKSE24,825.66326.711.33%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,880.4025.01-0.19%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,757.20118.201.37%
SSE Composite Index3,534.4817.660.50%

Market Movers